Folate-Dependent Hypermobility Syndrome
Methylation, the Extracellular Matrix, and a New Framework for Understanding Hypermobility Disorders

Core Propositions of This Article

• Folate-Dependent Hypermobility Syndrome (FDHS) is a clinically distinct subset of hypermobility spectrum disorders, driven by impaired one-carbon (methylation) metabolism affecting extracellular matrix integrity.
• Not all methylation cofactors are equivalent. The specific form of folate, B12, and betaine given to a patient — and the dose — determines whether supplementation helps, is neutral, or causes harm.
• Hypermobile EDS has no identified single causative gene. Claims that any one variant (including MTHFR) either explains or is irrelevant to hypermobility disorders reflect an incomplete understanding of complex, polygenic traits.
• A collaborative, gene-grouping approach is urgently needed to identify the multiple genetic pools that give rise to the variable presentations of hypermobility, mast cell activation syndrome (MCAS), and dysautonomia.
• Identifying FDHS is clinically actionable — but only with individualized metabolic and genetic testing to determine the correct forms and doses of methylation cofactors for each patient.

In This Article

1. Introduction: A Discovery Born from Clinical Observation
2. Methylation and the Extracellular Matrix: The Molecular Foundation
3. Not All Methylation Products Are the Same
4. Responding to Critics of MTHFR Research
5. No Single Gene Explains Hypermobility — And That’s the Point
6. A Call for Collaborative Gene-Grouping Research
7. Why Identifying FDHS Changes Clinical Outcomes
8. The Imperative of Individualized Testing
9. The COMT Caution: Why More Is Not Always Better
10. Conclusion: Precision Over Dismissal
11. References

Section 1

The patients who first led me to this hypothesis had already seen dozens of physicians. Their hypermobility was real and often debilitating. Their connective tissue was visibly lax. Yet their genetic testing — the panels typically ordered for Ehlers-Danlos syndrome and related conditions — came back unremarkable. They were told their hypermobility had no clear cause, that it was “just how they were built,” and that treatment was limited to physical therapy and pain management.

What I observed, however, was a pattern. These patients shared clinical features: fatigue disproportionate to their exertion level, neurological symptoms suggestive of autonomic dysfunction, recurrent inflammatory reactions consistent with mast cell involvement, and laboratory findings pointing toward impaired one-carbon (folate-methylation) metabolism. When their methylation pathway was supported with appropriate cofactors, a significant subset improved — not modestly, but substantially. Joint stability, pain levels, fatigue, and inflammatory burden all responded.

This clinical observation became the foundation for a formal research framework: Folate-Dependent Hypermobility Syndrome (FDHS) — a condition in which impaired folate-driven methylation disrupts the biosynthesis and structural integrity of the extracellular matrix (ECM), producing a phenotype clinically indistinguishable from, and often overlapping with, hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorder (HSD).¹

This article presents the biochemical and genetic evidence supporting FDHS, engages critically but respectfully with published dismissals of the methylation-hypermobility connection, and makes a broader call for a collaborative, gene-grouping scientific effort that can ultimately serve this underserved patient population more effectively than any single-gene framework ever could.

Section 2

To understand why folate metabolism is so consequential for connective tissue, one must first understand the indispensable role of methylation in building, remodeling, and stabilizing the extracellular matrix — the molecular scaffold that gives connective tissue its strength, elasticity, and structural organization.

The One-Carbon Cycle: A Universal Methyl-Donor System

Folate-driven one-carbon metabolism generates the universal methyl donor S-adenosylmethionine (SAM). SAM is the molecular currency of methylation across the entire genome and proteome — it donates methyl groups to DNA, histones, RNA, phospholipids, and proteins, regulating their structure and function.^2,3 The ratio of SAM to its byproduct S-adenosylhomocysteine (SAH) governs the methylation capacity of the cell: when this ratio falls — as it does in folate deficiency or MTHFR polymorphism — methylation of downstream targets is globally impaired.⁴

MTHFR (methylenetetrahydrofolate reductase) is the critical enzyme in this pathway. It converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-MTHF) — the only form of folate that can donate its methyl group to remethylate homocysteine back to methionine, which is then converted to SAM. When MTHFR activity is reduced by common variants such as C677T or A1298C, the flow of methyl groups through this cycle is slowed, SAM production is reduced, homocysteine accumulates, and the downstream methylation of ECM-related genes and proteins is compromised.⁵

How Methylation Directly Regulates ECM Genes

DNA methylation at CpG promoter sites is one of the primary mechanisms by which gene expression is regulated. ECM structural genes — including those encoding type I, III, and V collagens — are subject to methylation-dependent epigenetic regulation. Hypomethylation of collagen gene promoters drives inappropriate upregulation; hypermethylation suppresses synthesis when remodeling demands are high. The net effect of dysregulated methylation is disordered ECM gene expression, resulting in qualitatively and quantitatively abnormal collagen, fibronectin, and elastin production.^6,7

Matrix metalloproteinases (MMPs) — the enzymes responsible for ECM degradation and remodeling — are also methylation-regulated. The promoter region of MMP-9, for example, is controlled by CpG methylation status: when methylation is disrupted, MMP-9 expression increases inappropriately, accelerating the breakdown of structural collagen networks and contributing to connective tissue laxity.⁸ This alone provides a plausible mechanistic pathway from MTHFR-variant-driven undermethylation to the soft-tissue hypermobility and joint instability that characterize FDHS.

Homocysteine and the Breakdown of Collagen Cross-Linking

Perhaps the most direct link between folate-methylation impairment and hypermobility lies in the effect of elevated homocysteine on collagen cross-linking. Collagen fibrils derive their tensile strength from covalent cross-links between collagen molecules — a process mediated by the enzyme lysyl oxidase (LOX), which requires copper and oxidizes lysine and hydroxylysine residues to form stable intramolecular and intermolecular bonds. The cross-linked collagen fiber that results is mechanically strong and resistant to stretching.

Homocysteine — which accumulates when MTHFR activity is reduced — directly interferes with this process. The McKusick hypothesis, supported by substantial biochemical evidence and confirmed in human subjects with homocystinuria, holds that excess homocysteine reacts with the aldehyde groups on oxidized lysine residues, blocking the formation of normal cross-links and leaving collagen fibers weaker, more extensible, and more susceptible to mechanical failure.^9,10 This is not a theoretical risk. Classical homocystinuria — caused by complete absence of CBS (cystathionine beta-synthase) function — produces a Marfan-like connective tissue phenotype including joint hypermobility, lens dislocation, and scoliosis. The biochemical pathway is identical; only the severity differs in MTHFR variant carriers.

Prolyl and Lysyl Hydroxylation: The Collagen Quality Problem

Proper collagen synthesis requires two oxygen-dependent hydroxylation reactions: prolyl 4-hydroxylase (P4H) converts proline to hydroxyproline, and lysyl hydroxylase converts lysine to hydroxylysine. Both hydroxyproline and hydroxylysine are essential for the thermal stability of the triple helix and the formation of cross-links, respectively. These hydroxylase enzymes are sensitive to the cellular availability of iron, oxygen, vitamin C — and folate-dependent one-carbon metabolites, which participate in the redox environment supporting their activity.¹¹ When the folate-methylation cycle is impaired, the biosynthetic environment for hydroxylase function is compromised, producing collagen with a reduced hydroxyproline content, a less stable triple helix, and weaker cross-linking — exactly the molecular phenotype one would predict in hypermobile connective tissue.¹²

The mechanistic chain connecting MTHFR variants to connective tissue laxity:

MTHFR variant (C677T / A1298C) → Reduced 5-MTHF production → Reduced homocysteine remethylation → Elevated homocysteine + Reduced SAM → (1) Impaired CpG methylation of ECM genes (collagen, MMP regulation) + (2) Homocysteine interference with LOX-mediated collagen cross-linking + (3) Impaired prolyl/lysyl hydroxylation environment → Mechanically inferior, hypermobile connective tissue.

Each step in this chain is supported by published biochemistry. The full mechanism is detailed in: Courseault J et al., Heliyon, 2023 (PMID: 37123939).

Section 3

One of the most consequential — and most frequently misunderstood — aspects of FDHS treatment is this: the form of folate, vitamin B12, and betaine administered to a patient is not interchangeable. Giving the wrong form can be as unhelpful as giving nothing — and in some patients, it can actively cause harm. This distinction is central to why FDHS requires individualized metabolic and genetic evaluation rather than a one-size-fits-all supplement protocol.

Folate: Three Forms, Three Metabolic Fates

Folic acid — the synthetic, oxidized form found in most fortified foods and inexpensive supplements — requires conversion to dihydrofolate (DHF) and then to tetrahydrofolate (THF) via dihydrofolate reductase (DHFR), and ultimately to 5-MTHF via MTHFR, before it can participate in methyl donation. Here lies a fundamental problem: human hepatic DHFR activity is extraordinarily low and highly variable — approximately 50-fold slower than in rodents used in early safety studies.¹³ In patients with MTHFR variants, the folic acid supplementation strategy creates a metabolic traffic jam: unmetabolized folic acid (UMFA) accumulates in circulation, where it does not act as an active methyl donor but may actually competitively inhibit natural folate receptors and mask true cellular folate deficiency.¹⁴

Folinic acid (5-formyltetrahydrofolate, or leucovorin) enters the folate cycle one step downstream of DHFR and bypasses the folic acid–to–DHF conversion bottleneck. It still requires MTHFR to convert it to 5-MTHF for homocysteine remethylation. In patients with severe MTHFR variants, folinic acid can serve as a useful intermediate, particularly in those who experience adverse reactions to direct methylfolate supplementation (see Section 9 on COMT).

5-Methyltetrahydrofolate (5-MTHF) — the biologically active, reduced form — bypasses both DHFR and MTHFR entirely. It is the circulating form of folate that crosses cellular membranes and directly donates its methyl group to homocysteine via methionine synthase, generating methionine (and ultimately SAM). In patients with MTHFR C677T homozygosity, where enzyme activity may be reduced by up to 70%, direct supplementation with 5-MTHF is often the most effective pharmacological strategy.^15,16 However, the dose and the patient’s COMT status must be carefully considered (see Section 9).

Vitamin B12: Active Forms vs. Cyanocobalamin

Vitamin B12 is an essential cofactor for methionine synthase — the enzyme that converts homocysteine to methionine using the methyl group from 5-MTHF. Without adequate B12 function, even sufficient 5-MTHF cannot drive the remethylation cycle efficiently. As with folate, not all B12 forms are equivalent. Cyanocobalamin — the most common and cheapest form — requires detoxification (cyanide removal) and enzymatic conversion to the active forms methylcobalamin (for cytoplasmic methionine synthase) and adenosylcobalamin (for mitochondrial methylmalonyl-CoA mutase) before it can participate in methylation chemistry. Individuals with genetic variants in MTR (methionine synthase) or MTRR (methionine synthase reductase) may have impaired ability to perform these conversions.¹⁷

Methylcobalamin and hydroxocobalamin are generally preferred in patients with suspected methylation pathway variants, as they are more bioavailable in their active forms without requiring the same degree of hepatic conversion. For patients with autonomic dysfunction and neurological features — common in FDHS — the neurological bioavailability of methylcobalamin may offer additional benefit, as adequate methionine synthase activity is critical for myelin synthesis and autonomic nervous system maintenance.¹⁸

Betaine: The Backup Remethylation Donor

Betaine (trimethylglycine) provides an alternative — and critically important — route for homocysteine remethylation that does not depend on MTHFR or B12. Via betaine-homocysteine methyltransferase (BHMT), betaine donates one of its methyl groups directly to homocysteine, regenerating methionine in a folate-independent pathway. In patients with significant MTHFR impairment or poor tolerance of direct methylfolate supplementation, betaine can serve as a critical adjunct to lower homocysteine and provide additional SAM substrate. However, betaine must also be dosed carefully — excess methyl donation via this pathway in patients with slow COMT variants creates its own problems, as discussed in Section 9.

The broader lesson is that the methylation cycle is a tightly regulated, multi-input system. Each input — folate form, B12 form, betaine quantity, B6 status, riboflavin status — influences the net methylation capacity of the cell, and none of them can be evaluated or administered in isolation. This biochemical complexity is precisely why genetic testing for the full complement of one-carbon pathway variants, combined with functional metabolic markers, is essential before initiating treatment.

Section 4

Since the publication of the FDHS framework,¹ critics of MTHFR research have periodically argued that folate pathway variants have no meaningful role in connective tissue or hypermobility disorders. These positions deserve a careful, evidence-based response — because the patients affected by this condition deserve better than dismissal.

The Core Argument Against MTHFR — and Its Logical Flaw

The dismissal of MTHFR in hypermobility disorders typically runs as follows: MTHFR C677T and A1298C variants are common — present in 10–15% and 25–32% of the general population, respectively. Because they are common, they cannot explain a condition like hEDS. Because the ACMG has issued statements against routine MTHFR testing for general clinical indications, clinicians ordering it are engaging in low-value practice. Therefore, MTHFR is irrelevant to hypermobility.

This argument contains a fundamental error in reasoning: it conflates the irrelevance of MTHFR as a standalone disease-causing mutation with the potential relevance of MTHFR as a modifier variant in a polygenic complex trait. These are categorically different claims, and conflating them is not scientifically defensible.

The ACMG guidance — that MTHFR variants should not be ordered reflexively for nonspecific symptoms — was issued to prevent the overclinical interpretation of a common variant as a standalone diagnosis. It was never intended to argue that MTHFR variants cannot contribute to phenotypic complexity when combined with other genetic and metabolic variables. Extending that position to mean “MTHFR is biologically irrelevant in connective tissue disease” is a misapplication of a clinical utilization statement.

The Proof of Concept: Homocystinuria

If there were truly no biologically plausible connection between the one-carbon methylation pathway and connective tissue integrity, we would not expect to find a well-characterized human inborn error of this pathway producing connective tissue disease. We do. Classical homocystinuria, caused by severe deficiency of cystathionine beta-synthase (CBS), produces dramatically elevated homocysteine and results in a clinical syndrome that includes ectopia lentis, aortic dilation, scoliosis, and — notably — joint hypermobility and skin fragility that are frequently mistaken for Marfan syndrome or EDS.⁹ The mechanism by which homocysteine disrupts connective tissue — interference with lysyl oxidase cross-linking and collagen structure — is the same mechanism implicated in the more modest but real homocysteine elevation seen in symptomatic MTHFR variant carriers.¹⁰

This is not a theoretical extrapolation. It is direct evidence that the homocysteine-collagen cross-linking pathway is functional and consequential in humans. The question is not whether this pathway affects connective tissue — it clearly does — but rather at what threshold of homocysteine elevation does clinically significant connective tissue laxity emerge, and what other genetic and metabolic co-factors determine that threshold in any individual patient?

An Unresolved Contradiction in the Field

The field’s own 2017 international classification of Ehlers-Danlos syndromes — the definitive nosological document — explicitly acknowledges that hypermobile EDS has no identified causative gene.¹⁹ The hEDS diagnostic criteria are entirely clinical: they require a positive Beighton score, systemic connective tissue features, and functional impact — but not genetic confirmation, because none exists. The authors of that classification described hEDS as likely polygenic or multifactorial, with unknown genetic architecture.

Here is the contradiction: if hEDS has no known causative gene — if it is acknowledged to be polygenic and complex — then the categorical dismissal of MTHFR variants as “irrelevant” to this condition is logically insupportable. One cannot simultaneously argue that (a) the genetics of hEDS are unknown and complex, and (b) we are certain enough about those unknown genetics to rule out MTHFR’s participation. These two positions are mutually exclusive.

The scientifically rigorous position — the one this article advocates — is this: MTHFR variants do not cause hEDS in the classical monogenic sense. No one has claimed that they do. What FDHS proposes is that MTHFR variants, in combination with other genetic and metabolic variables, constitute one of several distinct mechanistic pathways through which connective tissue laxity and hypermobility syndrome can manifest. This is not a claim that MTHFR is the only answer. It is a claim that it is one meaningful piece of a far more complex puzzle.

Clinical Outcomes as Evidence

While the gold standard of randomized controlled trials has not yet been applied to FDHS treatment protocols (a gap that deserves to be filled by the research community), the clinical observation of meaningful improvement in a subset of hypermobile patients following methylation-targeted supplementation represents an important signal that should not be dismissed. The mechanistic rationale is sound; the clinical observations are consistent; the safety profile of appropriately dosed methylation support is favorable; and the patients who respond do so in ways that are difficult to attribute to placebo alone — particularly when their laboratory markers (homocysteine, methylmalonic acid, organic acid profiles) normalize in parallel with their clinical improvement.

Section 5

If one conclusion emerges with absolute consistency from three decades of genetic research in Ehlers-Danlos syndrome, it is this: the genetic basis of hypermobile EDS — the most common and most phenotypically variable subtype — remains unknown. The 13 molecularly defined EDS subtypes each have a defined genetic cause: pathogenic variants in genes encoding specific structural collagens (COL1A1/2, COL3A1, COL5A1/2), collagen-processing enzymes (ADAMTS2, PLOD1, SLC39A13), or non-collagen ECM components (TNXB, FKBP14). Hypermobile EDS stands apart: it meets clinical criteria but has resisted every attempt at molecular resolution.^19,20

This is not a trivial observation. The clinical heterogeneity of hEDS — in the degree of hypermobility, in the presence or absence of autonomic dysfunction, in mast cell involvement, in pain profile, in fatigue severity — strongly suggests that “hEDS” is not a single disease but a clinically convergent syndrome produced by multiple distinct biological mechanisms.^20,21 Two patients who both meet the 2017 hEDS criteria may share a phenotypic label while harboring entirely different underlying molecular pathologies.

This heterogeneity also explains why, despite enormous effort, genome-wide association studies (GWAS) in hEDS populations have not yet yielded a reproducible causative signal: when multiple distinct genetic mechanisms contribute to the same clinical phenotype, the statistical power of association studies is dramatically diluted unless the population is stratified by subtype.²² Finding the “hEDS gene” in an unstratified hypermobility cohort is like finding the “fever gene” in an unstratified population of febrile patients — the phenotype is real, but it reflects too many different underlying causes to resolve with a single genomic sweep.

The Mast Cell and Dysautonomia Constellation

The frequent co-occurrence of hEDS with mast cell activation syndrome (MCAS) and dysautonomia — particularly postural orthostatic tachycardia syndrome (POTS) — is a clinically well-recognized triad that has been described in the literature but poorly explained at the molecular level.²³ This triad provides an important clue: whatever genetic architecture underlies this phenotypic cluster affects not just structural connective tissue, but also the neuroimmune regulatory systems governing mast cell degranulation and autonomic nervous system function.

The methylation-mediated pathway is one of the few known biochemical systems that has plausible, mechanistically supported connections to all three features simultaneously:

• Connective tissue laxity: via impaired collagen cross-linking and ECM gene regulation, as detailed above.
• Mast cell dysregulation: Histamine — a key mast cell mediator — is catabolized in part by histamine N-methyltransferase (HNMT), which uses SAM as its methyl donor. When SAM levels are reduced by MTHFR-driven undermethylation, HNMT-mediated histamine clearance is impaired, allowing histamine and other mast cell mediators to accumulate at tissue level.²⁴ Separately, oxidative stress generated by homocysteine elevation can directly trigger mast cell degranulation, further amplifying the mast cell burden in susceptible individuals.
• Dysautonomia: Catecholamines — particularly norepinephrine and dopamine — are degraded via COMT (catechol-O-methyltransferase), which also requires SAM. In MTHFR variant carriers with already-reduced SAM production, the shared demand for SAM across histamine methylation, catecholamine methylation, and ECM gene methylation creates a competitive metabolic landscape in which all three pathways are simultaneously undersupported.²⁵ B12-dependent folate metabolism also directly supports myelin synthesis and peripheral autonomic nervous system integrity — and documented B12/folate insufficiency contributes to autonomic neuropathy.¹⁸

The folate-methylation axis is not the only mechanism that could explain the hEDS-MCAS-POTS triad — but it is one of the most mechanistically coherent, and it is the only one currently associated with a specific, testable, and treatable biochemical pathway.

Section 6

The scientific community has invested enormous resources searching for the single genetic explanation for hypermobile EDS. That search has so far been unsuccessful — not because hEDS has no genetic basis, but because we have been asking the wrong question. The productive question is not “what is the gene for hEDS?” It is: “what are the gene groupings — the distinct molecular subtypes — that produce the clinical syndrome we call hEDS, and can we identify, stratify, and treat each subtype individually?”

This reframing is not merely semantic. It is the difference between a research paradigm that has repeatedly failed and a research paradigm that has the potential to actually help patients. If hEDS encompasses multiple distinct biological mechanisms, then identifying those mechanisms — and the gene groupings that define them — makes diagnosis more precise and treatment more targeted. This is the future of connective tissue medicine, and it is a future that requires collaboration, not competition, among the many research groups working in this space.

Folate-Dependent Hypermobility Syndrome represents one such gene grouping: patients in whom variants in MTHFR, MTR, MTRR, COMT, CBS, DHFR, or other one-carbon metabolism genes combine to reduce methylation capacity below the threshold required for adequate ECM maintenance. Other groupings likely exist — involving variants in type V collagen genes not severe enough to meet classical EDS criteria, in tenascin-X (TNXB) haploinsufficiency, in collagen cross-linking enzymes, in TGF-β signaling, and in connective tissue regulatory pathways not yet characterized. Each grouping may have a distinct clinical signature and a distinct treatment response.

The goal is not to claim that FDHS explains all hypermobility. The goal is to identify it within the broader population of hypermobile patients — with appropriate testing — so that the patients who fall into this subgroup can be offered effective treatment, while others are appropriately directed toward investigation of other pathways. This is precision medicine applied to connective tissue disease.

Section 7

The most compelling argument for the clinical relevance of FDHS is not theoretical — it is the existence of a treatment pathway. Unlike the majority of hypermobility presentations, for which clinicians can offer physical therapy, bracing, and pain management but not address underlying pathophysiology, FDHS offers a target: the methylation cycle. When that target is identified and appropriately supported, the downstream consequences — for connective tissue, for mast cell stability, for autonomic function — can improve in measurable, meaningful ways.

Patients in whom FDHS is identified and properly managed have demonstrated improvements across several clinical domains:

• Connective tissue and joint stability: Reduction in subluxation frequency, improved proprioceptive function, and enhanced tolerance of physical rehabilitation — consistent with improved collagen quality over time as cross-linking is restored.
• Mast cell burden: Reduction in histamine-mediated symptoms (flushing, urticaria, reactive airways, gastrointestinal dysmotility, and neurological symptoms) attributable to restored HNMT-mediated histamine clearance.
• Autonomic function: Improved orthostatic tolerance, reduction in tachycardia with positional change, and improved thermoregulation — consistent with normalized catecholamine methylation via COMT and improved peripheral nerve health via B12-dependent myelin support.
• Fatigue and cognitive function: Brain fog and fatigue — hallmark complaints in hEDS — show measurable improvement in patients whose methylation capacity is restored, likely through multiple mechanisms including improved mitochondrial function and reduced neuroinflammation from decreased homocysteine-driven oxidative stress.
• Laboratory normalization: Homocysteine levels, methylmalonic acid, and organic acid profiles reflecting one-carbon metabolism return toward normal ranges with appropriate supplementation, providing objective evidence of metabolic response.

It is important to state clearly: FDHS is not a complete cure for hypermobility. Structural laxity that has developed over years cannot be fully reversed by metabolic correction alone, and physical rehabilitation remains essential. But the degree to which methylation support reduces the biological burden on already-compromised connective tissue, reduces inflammatory load, and improves neural and autonomic function can make the difference between rehabilitation success and rehabilitation failure — between a patient who improves with physical therapy and one who doesn’t.

That is a clinically meaningful difference. And it is accessible only to patients who are correctly identified as having FDHS rather than being told, again, that their hypermobility has no treatable biological cause.

Section 8

The same biochemical complexity that makes FDHS clinically important also makes individualized testing non-negotiable. Ordering MTHFR genotyping alone — without the metabolic context, without understanding the full gene complement of the one-carbon cycle, and without knowing the patient’s COMT status — is insufficient. It can produce a false sense of certainty in either direction: a negative MTHFR result does not exclude methylation pathway impairment (variants in other one-carbon pathway genes can produce equivalent effects), and a positive MTHFR result does not automatically define the correct treatment.

Genetic Testing: The One-Carbon Pathway

Comprehensive evaluation for FDHS looks beyond a single gene to assess the full architecture of the one-carbon cycle.¹⁴ Key players in this pathway include the enzymes responsible for folate conversion, homocysteine remethylation, transsulfuration, and catecholamine clearance — among others. What matters clinically is not any individual variant in isolation, but how these variants combine to affect the overall methylation capacity of the cell. A comprehensive gene panel evaluating the one-carbon pathway as an integrated system — rather than as a checklist of individual mutations — provides the most actionable picture. Equally important is COMT status, which directly governs how safely and at what dose methylation support can be administered (see Section 9).

Functional Metabolic Markers

Genetic testing tells us what a patient is at risk for; functional metabolic markers tell us what is actually happening in the patient’s biochemistry right now. Both are necessary for safe and effective FDHS management. Relevant markers may include indicators of homocysteine load, functional B12 status, intracellular folate stores, and organic acid intermediates that reflect active one-carbon pathway impairment — findings that can be abnormal even when standard “normal range” laboratory values appear reassuring.¹⁸ Cofactor status relevant to collagen cross-linking and hydroxylation rounds out the metabolic picture.

A critical point that cannot be overstated: laboratory reference ranges are population-derived averages, not individualized thresholds. A value that falls within the “normal” range may still be functionally inadequate for a patient with specific genetic variants that raise their metabolic requirements. Conversely, a result that appears modestly elevated may carry significant clinical implications in the context of a hypermobility phenotype. Interpreting these results accurately requires a clinician — physician, nurse practitioner, or physician assistant — with specific training in metabolic genetics and one-carbon pathway biochemistry. Results should never be self-interpreted or used to self-direct supplementation protocols.

The Genomics Performance Screen (GPS)

The Genomics Performance Screen (GPS), available through The Fascia Institute and Treatment Center in New Orleans and Los Angeles clinic, provides a comprehensive genomic evaluation designed to assess the full one-carbon pathway and related metabolic networks in a clinically integrated format. Rather than returning a list of raw variants for the patient to interpret alone, GPS results are reviewed in the context of the patient’s full clinical picture by a clinician experienced in FDHS and methylation-related connective tissue disorders. This is the testing framework we use to identify FDHS, determine the correct form and dose of methylation support, assess COMT status before prescribing, and establish a baseline for ongoing monitoring. If you are a hypermobile patient who has never had this level of metabolic evaluation, contact us to discuss whether GPS evaluation is appropriate for your presentation.

Section 9 — Clinical Safety

If one principle above all others must be communicated to patients, clinicians, and researchers engaging with FDHS treatment, it is this: more methylation support is not always better, and in some patients it is actively harmful. This is not a reason to avoid methylation support — it is a reason to individualize it through testing before prescribing.

The gateway to understanding why is the COMT gene. COMT (catechol-O-methyltransferase) is the enzyme responsible for the SAM-dependent methylation and inactivation of catecholamines — dopamine, norepinephrine, epinephrine — and estrogen metabolites. The Val158Met variant of COMT (rs4680) produces a 3–4-fold reduction in enzyme activity compared to the high-activity Val/Val genotype.^25,26 Individuals who are Met/Met homozygotes at this locus have significantly slower catecholamine clearance.²⁷

Here is the clinical significance for FDHS management: when a patient with slow COMT (Met/Met) is given high-dose methyl donors — whether as 5-MTHF, methylcobalamin, or betaine — the influx of methyl groups drives catecholamine methylation at an accelerated rate, but the slow COMT enzyme creates a substrate-product imbalance. The result can be an accumulation of partially oxidized catecholamine metabolites, an excessive depletion of SAH (inhibiting feedback control), and a clinical syndrome characterized by anxiety, overstimulation, irritability, racing thoughts, increased heart rate, and insomnia — all of which are paradoxically worse on methylation support than off it.

The High-Dose B Vitamin Problem

There is a concerning pattern in the wellness and functional medicine supplement market: multi-gram doses of B vitamins — particularly B6 (pyridoxine), B12, and high-dose methylfolate — marketed aggressively to patients with fatigue, brain fog, or known MTHFR variants. These products are widely available without a prescription, frequently promoted in online communities for hypermobile and dysautonomia patients, and often self-administered at doses far exceeding what any clinician would recommend following proper evaluation. This is a real source of harm.

High-dose B6 (pyridoxine), in particular, is directly neurotoxic at sustained elevated doses — causing a sensory peripheral neuropathy that mimics and worsens the very symptoms hypermobile patients are trying to address: burning, tingling, numbness, and proprioceptive loss. This is not a rare or theoretical risk; it is a documented clinical syndrome that has been reported with long-term supplementation at doses commonly found in B-complex supplements sold in health food stores. For patients whose hypermobility already compromises proprioception and joint position sense, B6 neuropathy is a particularly dangerous additive injury.

Excess methylfolate and methylcobalamin in COMT-slow individuals — as described above — can trigger a neurological and cardiovascular activation syndrome that is frightening, destabilizing, and in some patients, severe enough to require dose reversal and temporary discontinuation. Patients who have experienced this and then stopped all methylation support are left undertreated for their underlying FDHS, often concluding that “methylation supplements don’t work for me” — when the real issue was dose, form, and the absence of COMT-informed prescribing.

The responsible clinical message is not to avoid B vitamins — it is to take them only at doses determined by a qualified clinician who has reviewed your full genetic and metabolic picture. A product’s label dose is a regulatory limit, not a therapeutic recommendation. For FDHS patients, it is almost never appropriate.

Patients who are COMT Met/Met homozygotes often tolerate folinic acid or hydroxocobalamin better

…than direct methylfolate or methylcobalamin, because these forms support the methylation cycle without the same degree of immediate methyl group loading. Betaine dosing must be carefully titrated. In some COMT-slow patients, a very gradual dose escalation of methylation support over weeks to months is the only well-tolerated approach. Similarly, too little support — insufficient dosing, wrong form, or improper cofactor balance — leaves the underlying deficit uncorrected. The therapeutic window is real and must be found through testing, monitoring, and individualized dose optimization.

Supplementation Is a Long-Term Commitment — and So Is Monitoring

Because FDHS is driven by genetic variants that do not change over a lifetime, methylation support is not a short-term intervention — it is an ongoing physiological requirement. Patients who achieve clinical improvement and then discontinue supplementation typically see regression of gains as homocysteine rises, SAM falls, and ECM maintenance is again compromised. This is not a failure of the treatment; it is the expected consequence of removing support from a pathway that cannot self-correct genetically.

Equally important, long-term methylation support requires periodic monitoring. Metabolic needs shift with age, hormonal changes, illness, stress, and changes in diet or body composition. Doses that were appropriate at one stage of life may be insufficient or excessive at another. A follow-up metabolic workup — ideally at regular intervals determined by the treating clinician — is necessary to confirm that the methylation pathway remains adequately supported without overshoot. This is not a set-it-and-forget-it protocol; it is an ongoing therapeutic relationship between patient and clinician.

At The Fascia Institute’s Hypermobility Clinic, ongoing monitoring of FDHS patients is built into the treatment model — because we understand that the biochemistry of connective tissue is not static, and that effective treatment of a lifelong condition requires lifelong clinical engagement.

This is why FDHS treatment — despite involving supplements rather than pharmaceuticals — requires the same level of clinical rigor, individualization, and monitoring as any long-term prescription therapeutic protocol.

Section 10

The history of medicine is full of examples in which a biologically important mechanism was dismissed before its clinical significance was fully appreciated — either because the initial evidence was correlational rather than causal, because the involved variants were “too common to be relevant” in the eyes of those unfamiliar with polygenic modifier biology, or because the mechanism crossed disciplinary boundaries that made it invisible to specialists focused on a single domain.

Folate-Dependent Hypermobility Syndrome asks clinicians and researchers to hold two things in mind simultaneously: the intellectual humility to acknowledge that hEDS has no known single-gene cause, and the scientific rigor to investigate the polygenic, metabolic, and epigenetic mechanisms that fill that explanatory gap. FDHS is not the complete answer to hypermobility. It is one important answer — one that is testable, treatable, and increasingly supported by published research.

What this field most needs is not a single definitive study proclaiming one mechanism correct and all others wrong. What it needs is a collaborative, hypothesis-generating, gene-grouping research effort that takes the heterogeneity of the hypermobility population seriously — that develops stratified clinical cohorts, applies comprehensive metabolic and genomic profiling, and tests targeted interventions within each identified subgroup. FDHS patients deserve inclusion in that effort, not exclusion from it.

Until then, the clinician’s obligation is clear: identify the patients who fall within the FDHS phenotype, test them properly, treat them individually, and monitor their response with the same rigorous attention to biochemical markers and clinical outcomes that we bring to any complex metabolic condition. These are not patients who lack a diagnosis. They are patients who, for too long, have been given the wrong framework. If you believe you or your patient may fall within this phenotype, learn more about our Hypermobility Clinic or explore Genomics Performance Screen (GPS) testing as a first step.

References

1. Courseault J, Kingry C, Morrison J, Lanoux M, Bix G, Avila A, Burbank A, Doherty DA. Folate-dependent hypermobility syndrome: A proposed mechanism and diagnosis. Heliyon. 2023 Apr 18;9(4):e15387. doi: 10.1016/j.heliyon.2023.e15387. PMID: 37123939; PMCID: PMC10149321.
2. Locasale JW. Serine, one-carbon metabolism, and cancer. Nat Rev Cancer. 2013 Aug;13(8):572–83. doi: 10.1038/nrc3557. PMID: 23619118.
3. Mentch SJ, Mehrmohamadi M, Huang L, et al. Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. Cell Metab. 2015 Nov 3;22(5):861–73. doi: 10.1016/j.cmet.2015.08.024. PMID: 26411341.
4. Ulrey CL, Liu L, Andrews LG, Tollefsbol TO. The impact of metabolism on DNA methylation. Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R139–47. doi: 10.1093/hmg/ddi100. PMID: 15809266.
5. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May;10(1):111–3. doi: 10.1038/ng0595-111. PMID: 7647779.
6. Bechtel W, McGoohan S, Zeisberg EM, et al. Methylation controls the intronic enhancer of the ECM1 gene via methylation-sensitive transcription factors. Kidney Int. 2010 Mar;77(6):492–9. doi: 10.1038/ki.2009.487. PMID: 20072112.
7. Sanders YY, Ambalavanan N, Halloran B, et al. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012 Mar 15;185(6):661–71. doi: 10.1164/rccm.201107-1288OC. PMID: 22108194.
8. Chicoine E, Esteve PO, Robledo O, et al. Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem Biophys Res Commun. 2002 Feb 22;291(3):713–8. doi: 10.1006/bbrc.2001.6500. PMID: 11866535.
9. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GH. Evidence for McKusick’s hypothesis of deficient collagen cross-linking in patients with homocystinuria. Pediatr Res. 1996 Oct;40(4):590–6. doi: 10.1203/00006450-199610000-00020. PMID: 8825392.
10. Eyre DR, Paz MA, Gallop PM. Cross-linking in collagen and elastin. Annu Rev Biochem. 1984;53:717–48. doi: 10.1146/annurev.bi.53.070184.001205. PMID: 6148703.
11. Stover PJ, Field MS. Trafficking of intracellular folates. Adv Nutr. 2011 Jul;2(4):325–31. doi: 10.3945/an.111.000596. PMID: 22332061.
12. Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003 Apr;22(1):15–24. doi: 10.1016/S0945-053X(03)00006-4. PMID: 12782141.
13. Bailey SW, Ayling JE. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. Proc Natl Acad Sci USA. 2009 Sep 8;106(36):15424–9. doi: 10.1073/pnas.0902072106. PMID: 19706381.
14. Stover PJ. Physiology of folate and vitamin B12 in health and disease. Nutr Rev. 2004 Jun;62(6 Pt 2):S3–12. doi: 10.1111/j.1753-4887.2004.tb00070.x. PMID: 15497621.
15. Scaglione F, Panzavolta G. Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica. 2014 May;44(5):480–8. doi: 10.3109/00498254.2013.845705. PMID: 24494987.
16. Lamers Y, Prinz-Langenohl R, Moser R, Pietrzik K. Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women. Am J Clin Nutr. 2004 Mar;79(3):473–8. doi: 10.1093/ajcn/79.3.473. PMID: 15321799.
17. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe MTHFR deficiency. Am J Hum Genet. 1995 May;56(5):1052–9. PMID: 7668266.
18. Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med. 2013 Jan 10;368(2):149–60. doi: 10.1056/NEJMcp1113996. PMID: 23364733.
19. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):8–26. doi: 10.1002/ajmg.c.31552. PMID: 28306229.
20. Tinkle B, Castori M, Berglund B, et al. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): clinical description and natural history. Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):48–69. doi: 10.1002/ajmg.c.31538. PMID: 28306230.
21. Hakim A, De Wandele I, O’Callaghan C, Pocinki A, Rowe P. Chronic fatigue in Ehlers-Danlos syndrome — Hypermobile type. Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):175–80. doi: 10.1002/ajmg.c.31542. PMID: 28306239.
22. Bowen JM, Sobey GJ, Burrows NP, et al. Ehlers-Danlos syndrome, classical type. Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):27–39. doi: 10.1002/ajmg.c.31548. PMID: 28306228.
23. Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med. 2015 Jul 9;373(2):163–72. doi: 10.1056/NEJMra1409760. PMID: 26267623.
24. Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007 May;85(5):1185–96. doi: 10.1093/ajcn/85.5.1185. PMID: 17490952.
25. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996 Jun;6(3):243–50. doi: 10.1097/00008571-199606000-00007. PMID: 8807664.
26. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol. 1999;39:19–52. doi: 10.1146/annurev.pharmtox.39.1.19. PMID: 10331090.
27. Männistö PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999 Dec;51(4):593–628. PMID: 10353985.
28. Raj SR. Postural tachycardia syndrome (POTS). Circulation. 2013 Jun 11;127(23):2336–42. doi: 10.1161/CIRCULATIONAHA.112.144501. PMID: 23547177.
29. Obeid R, Holzgreve W, Pietrzik K. Is 5-methyltetrahydrofolate an alternative to folic acid for the prevention of neural tube defects? J Perinat Med. 2013 Sep;41(5):469–83. doi: 10.1515/jpm-2012-0256. PMID: 23482308.

Disclosure: Dr. Jacques Courseault, MD is the founder of The Fascia Institute and Treatment Center® and a clinical faculty member at Tulane University School of Medicine. He is the primary author of the Folate-Dependent Hypermobility Syndrome framework and the corresponding Heliyon publication cited herein (PMID: 37123939). This educational article reflects his clinical and research perspective and should be interpreted in that context. All referenced literature is independently published and peer-reviewed. This article is intended for educational purposes; it does not constitute individualized medical advice. Patients should work with a qualified clinician experienced in metabolic genetics and connective tissue disorders before initiating any testing or treatment protocol.